A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)
Satoru Miura(Niigata Cancer Center Hospital), Hirohisa Yoshizawa(Niigata University Medical and Dental Hospital), Akihiko Gemma(Nippon Medical School), Yuichi Takiguchi(Sanno Medical Center), Kunihiko Kobayashi(Saitama International Medical Center), Taku Nakagawa(Saint John's Health Center), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Takashi Ishida(Keio University), Toshiyuki Harada(Hokkaido hospital), Akira Iwashima, Hiroshi Watanabe(Tohoku University), Shunichi Sugawara(Sendai Kousei Hospital), Masaki Terada, Akira Inoue(Tohoku University Hospital), Hiroshi Kagamu(Saitama International Medical Center)
Cited by 7
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695